Abstract:Luteolin (LU, 5,7,3′,4′-tetrahydroxyflavone) most active compound in Chinese herbal flavones has been acting as a antimicrobial, anti-inflammatory, anti-cancer, and antimutagen. However, its poor bioavailability, hydrophobicity, and pharmacokinetics restrict clinical application. Here in this study, LU-loaded solid lipid nanoparticles have been prepared by hot-microemulsion ultrasonic technique to improve the bioavailability & pharmacokinetics of compound. LU-loaded solid lipid nanoparticle size was confirmed by particle size analyzer with range from 47 to 118 nm, having zepta potential −9.2 mV and polydisperse index 0.247, respectively. Round-shaped SLNPs were obtained by using transmission electron microscope, and encapsulation efficiency 74.80 % was calculated by using HPLC. Both in vitro and vivo studies, LC–MS/MS technique was used for quantification of Luteolin in rat. The T max value of drug with LU–SLNs after the administration was Ten times shorter than pure Luteolin suspension administration. C max value of drug after the administration of LU–SLNs was five times higher than obtained with native drug suspension. Luteolin with SLNs has increased the half-life approximately up to 2 h. Distribution and clearance of drug with SLNs were significantly decreased by 2.16–10.57 fold, respectively. In the end, the relative bioavailability of SLNs has improved about 4.89 compared to Luteolin with SLNs. From this study, it can be concluded that LU–SLNs have not only great potential for improving solubility but also increased the drug concentration in plasma. Furthermore, use of LC–MS/MS for quantification of LU–SLNs in rat plasma is reliable and of therapeutic usefulness, especially for neurodegenerative and cancerous disorders in humans.

Preparation of oridonin-loaded solid lipid nanoparticles and studies on them in vitro and in vivo

Studies on preparation and property of oridonin solid lipid nanoparticles

Preparation And Characteristics Of Oridonin-Loaded Nanostructured Lipid Carriers As A Controlled-Release Delivery System

In Vivo Studies On The Oridonin-Loaded Nanostructured Lipid Carriers

Studies on the Oridonin-Loaded Poly(d,l-Lactic Acid) Nanoparticles in Vitro and in Vivo

In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers

Preparation and Characterization of Oridonin-loaded Poly (caprolactone)-Poly (ethylene oxide)-Poly (caprolactone) Copolymer Nanoparticles

Optimization and Evaluation of Oridonin-loaded Soluplus®-Pluronic P105 Mixed Micelles for Oral Administration

Preparation of puerarin solid lipid nanoparticles for oral administration

Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil

Preparation and in Vitro, in Vivo Evaluations of Norfloxacin-Loaded Solid Lipid Nanopartices for Oral Delivery

Preparation and characterization of oleanolic acid-loaded solid lipid nanoparticles for oral administration

Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.

[The Tissue Distribution in Mice and Pharmacokinetics in Rabbits of Oridonin-Solid Lipid Nanoparticles].

Preparation and in Vitro Properties of Oridonin-Loaded Polylactic-acid Nanoparticles

Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies

Development and in-vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique.

In vitro and in vivo studies of lipid-based nanocarriers for oral N<sub>3</sub>-o-toluyl-fluorouracil delivery

Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.

Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement.